Merckle Sees Potential In CareDx (CDNA); Bullish Volatility In Biostar Pharma (BSPM)

 

http://galaxystocks.com/wp-content/uploads/2016/06/CareDx_CDNA.png

After the closing bell on Friday, Merckle International GmbH disclosed in a regulatory filing with the U.S. Securities and Exchange Commission (SEC) a 5.1% stake (1,118,830 shares) in CareDx Inc. (Nasdaq:CDNA), also indicating that it plans to acquire more – up to 20% of the shares outstanding of the molecular diagnostics company in the future

CDNA stock finished the regular session at $4.75, down $0.05 (or -1.04%) and 67,221 of its shares shares changed hands during the day

CareDx, which focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients, has 14.29M Shares Outstanding, Market Capitalization (intraday) of $67.9M and CDNA stock one-year range is between $3.70 and $8.00 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Biostar_Pharmaceuticals_BSPM.jpg

Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM) stock soared to touch the $5.59 mark in intraday trading Friday to finally close at $4.27, up $1.00 (30.58%) with a total volume of 8,608,833 shares traded during the day, representing a large increase in activity versus its average volume (3m) of 530,282.

However, there appears to be no relevant recent news from the pharmaceutical company in the street that may explain this movement in the stock

Biostar Pharmaceuticals, which develops, manufactures, and markets pharmaceutical and health supplement products in China, has 2.21M Shares Outstanding, Market Capitalization (intraday) of $9.44M and BSPM stock 52-week range is from $1.08 to $8.40 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/